Ligand Pharmaceuticals Incorporated (LGND) is a Biotechnology company in the Healthcare sector, currently trading at $225.09. It has a SharesGrow Score of 77/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of LGND = $109.26 (-51.5% from the current price, the stock appears overvalued). Analyst consensus target is LGND = $248 (+10.2% upside).
Valuation: LGND trades at a trailing Price-to-Earnings (P/E) of 32.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.21.
Financials: revenue is $268M, +18.2%/yr average growth. Net income is $124M, growing at +1392.7%/yr. Net profit margin is 46.4% (strong). Gross margin is 97.5% (+24.4 pp trend).
Balance sheet: total debt is $451M against $1.0B equity (Debt-to-Equity (D/E) ratio 0.44, conservative). Current ratio is 22.23 (strong liquidity). Debt-to-assets is 28.9%. Total assets: $1.6B.
Analyst outlook: 12 / 17 analysts rate LGND as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 55/100 (Partial), Growth 90/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 70/100 (Pass), Future 73/100 (Pass), Income 100/100 (Pass).
